The estimated Net Worth of David D Chang is at least 22.2 百万$ dollars as of 15 March 2022. David Chang owns over 23,648 units of Allogene Therapeutics Inc stock worth over 6,662,887$ and over the last 8 years he sold ALLO stock worth over 4,304,030$. In addition, he makes 11,192,100$ as President、 Chief Executive Officer、 Co-Founder、 Director at Allogene Therapeutics Inc.
David has made over 11 trades of the Allogene Therapeutics Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 23,648 units of ALLO stock worth 180,907$ on 15 March 2022.
The largest trade he's ever made was exercising 60,000 units of Allogene Therapeutics Inc stock on 1 March 2017 worth over 413,400$. On average, David trades about 7,562 units every 58 days since 2016. As of 15 March 2022 he still owns at least 2,289,652 units of Allogene Therapeutics Inc stock.
You can see the complete history of David Chang stock trades at the bottom of the page.
Dr. David Chang, M.D. Ph.D., serves as President, Chief Executive Officer, Co-Founder, Director of the Company. Prior to joining us, Dr. Chang served as the Chief Medical Officer and Executive Vice President, Research and Development of Kite from June 2014 until March 2018. Dr. Chang previously held senior positions at Amgen Inc., a biopharmaceutical company, including Vice President, Global Development from July 2006 to May 2014, Senior Director, Oncology-Therapeutics from July 2005 to June 2006 and Director, Medical Sciences from December 2002 to June 2005. Prior to that, he was an Associate Professor at the University of California, Los Angeles School of Medicine. He has also served as a Venture Partner of Vida Ventures, LLC since November 2017, and Two River Consulting, LLC since October 2017. Dr. Chang obtained a B.S. in Biology from the Massachusetts Institute of Technology and an M.D. and Ph.D. from Stanford University.
As the President、 Chief Executive Officer、 Co-Founder、 Director of Allogene Therapeutics Inc, the total compensation of David Chang at Allogene Therapeutics Inc is 11,192,100$. There are no executives at Allogene Therapeutics Inc getting paid more.
David Chang is 60, he's been the President、 Chief Executive Officer、 Co-Founder、 Director of Allogene Therapeutics Inc since 2018. There are 6 older and 14 younger executives at Allogene Therapeutics Inc. The oldest executive at Allogene Therapeutics Inc is David Bonderman, 77, who is the Lead Independent Director.
Over the last 6 years, insiders at Allogene Therapeutics Inc have traded over 137,494,387$ worth of Allogene Therapeutics Inc stock and bought 2,891,304 units worth 29,333,135$ . The most active insiders traders include Group Holdings (Sbs) Adviso...、Arie Belldegrun、Inc Pfizer. On average, Allogene Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of 286,894$. The most recent stock trade was executed by Deborah M. Messemer on 18 June 2024, trading 18,641 units of ALLO stock currently worth 42,501$.
allogene therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor t-cell (car t) therapy directed at blood cancers and solid tumors. founded and led by former kite pharma executives who bring unrivaled clinical development acumen in cell therapy, allogene is well-positioned to further the potential of allogeneic cell therapy for patients. allogeneic car t therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. this approach eliminates the need to create personalized therapy from a patient’s own cells, simplifies manufacturing, and reduces the time patients must wait for car t treatment. the allogene portfolio includes 16 pre-clinical t cell therapy assets and ucart19, an allogeneic car t therapy currently in phase 1 development for the treatment of acute lymphoblastic leukemia (all). through its notable partnerships, allogene le
Allogene Therapeutics Inc executives and other stock owners filed with the SEC include: